Eradication of proliferative verrucous leukoplakia with toll-like receptor 7 agonist (topical imiquimod): a case report

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 15, 2024

Proliferative verrucous leukoplakia (PVL) is an aggressive and distinct type of oral precancerous lesion characterized by warty surfaced white plaque diffusely involving mucosa. Surgical excision the treatment choice. However, PVL has persistent recurrent growth patterns, requiring multiple surgical procedures. intervention especially challenging if extends between teeth limiting access. These interproximally located lesions have a high propensity to undergo malignant transformation. We report case 53-year-old man with covering maxillary mandibular gingiva. Despite complete excisions, recurred, focal area in interproximal gingiva progressed invasive squamous cell carcinoma marginal resection. The remaining areas were treated topical imiquimod (toll-like receptor 7 agonist) for six months, resulting clinical histological resolution. Topical agents can cover larger surface penetrate areas. Importantly, it allows maximal local exposure minimal systemic toxicity, essential long-term prophylactic use agent prevent relapse.

Language: Английский

---

Mimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs

Investigative Ophthalmology & Visual Science, Journal Year: 2024, Volume and Issue: 65(14), P. 14 - 14

Published: Dec. 5, 2024

Purpose: Refractory or recurrent retinoblastoma results from acquired chemoresistance and the management of these eyes often requires surgical removal. Our objective was to develop models resistant chemotherapy by exposing cancer cells repeated mimicking clinical scenario. These newly were used evaluate potential novel therapies. Methods: Chemoresistant obtained two primary cell cultures three weekly doses melphalan topotecan. The sensitivity each evaluated, cross-resistance topotecan, melphalan, carboplatin assessed. Genomic alterations differential expression efflux/influx transporters between chemoresistant parental analyzed. Subsequently, both repurposed agents digoxin, methylene blue, gemcitabine Results: Four successfully established, showing significantly higher half-maximal inhibitory concentration (IC50) values for topotecan compared their corresponding (P < 0.05). Cross-resistance demonstrated, with a 3-fold increase in IC50. also showed reduced 0.05) cells, whereas evaluated remained unchanged. analysis revealed no selective although influx/efflux observed across all models. Conclusions: In vitro simulation patient treatment useful establish retinoblastomas identify strategies overcome resistance through drug repurposed. warrant further investigation support translation.

Language: Английский

---

Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Dec. 8, 2024

Language: Английский

---

Impact of Rhenium(I)-Diselenoether Compound on Cell Adhesion, Migration, Invasion Capacities, and MMP-2 Release in MDA-MB-231 Breast Cancer Cells

Anticancer Research, Journal Year: 2024, Volume and Issue: 45(1), P. 73 - 79

Published: Dec. 30, 2024

Background/Aim: Organometallic complexes can decrease adhesion, migration, invasion of cancer cells, mainly through regulation the extracellular matrix and therefore act against metastases. The aim was to investigate anti-invasive properties a rhenium-based metal compound, rhenium(I)-diselenoether (Re-diSe) its effects on metalloproteinase MMP-2, key player in metastatic processes, cultured MDA-MB231 triple-negative breast cells. Materials Methods: Matrigel utilized assess cell adhesion matrix. Migration capacity evaluated wound healing assay, while assays were conducted using transwell assay by crystal violet dye. MMP-2 levels quantified medium fluorometric kit assay. Cells exposed increasing concentrations drug (5, 10, 20, 50 100 μM). Three time points exposure cells investigated (48, 96 120 h). Results: Re-diSe exhibited effectiveness even at doses as low 5 or 10 μM all biological assays. h significantly improved effect comparison with 48 h. Conclusion: results highlight impact

Language: Английский

---

Molecular Iodine Improves the Efficacy and Reduces the Side Effects of Metronomic Cyclophosphamide Treatment against Mammary Cancer Progression

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8822 - 8822

Published: Aug. 13, 2024

Metronomic chemotherapy with cyclophosphamide (Cpp) has shown promising results in cancer protocols. These lower and prolonged doses have antiangiogenic, pro-cytotoxic, moderate secondary effects. Molecular iodine (I2) reduces the viability of cells and, chemotherapeutic agents, activates antitumoral immune response diminishes side The present work evaluates adjuvant oral I2 Cpp using a murine model mammary cancer. Female Sprague Dawley rats 7,12-dimethylbenzantracene-induced tumors received intraperitoneal (50 70 mg/kg two times/week, iCpp50 iCpp70) (0.03%; 50 mg/Kg; oCpp50) doses. (0.05%, mg/100 mL) oCpp50 were offered drinking water for three weeks. iCpp70 was most efficient dose but generated severe body weight loss hemorrhagic cystitis (HC). prevented loss, exhibited actions Cpp, decreasing tumor growth, canceled HC mechanisms, including decreases vascular endothelial growth factor (VEGF) Survivin expression. + diminished angiogenic signals (CD34, vessel-length, VEGF content) proinflammatory cytokines (interleukin-10 necrosis factor-alpha) increased cytotoxic (lymphocytic infiltration, CD8+ cells, Tbet, interferon-gamma) antioxidant markers (nuclear erythroid factor-2 glutathione peroxidase). enhances effectiveness oCpp, making it compelling candidate clinical protocol.

Language: Английский

---